GlassScriptPhysician profile
Edgar Argulian
NPI 1689824591
$3,573.47
in general payments reported to CMS, 2019-2025
24 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.45 · 2020: $517 · 2021: $197 · 2022: $563 · 2023: $466 · 2024: $1,209 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538 · Travel and Lodging: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.67 |
| Travel and Lodging | $710.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,109.88 | 2024-2025 | Navitor, Amplatzer Amulet, Mitraclip |
| Heartflow, INC. | $413.43 | 2023-2025 | Ffrct |
| Amgen INC. | $306.69 | 2020-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $174.63 | 2022-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $164.12 | 2020 | |
| Boston Scientific Corporation | $158.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $148.88 | 2020-2024 | Xarelto |
| Pfizer INC. | $130.29 | 2020-2024 | |
| Medtronic, INC. | $130.15 | 2022 | |
| Lantheus Medical Imaging, INC. | $104.66 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.34 | 2020 | |
| Edwards Lifesciences Corporation | $94.08 | 2024 | Pascal |
| Astrazeneca Pharmaceuticals LP | $86.36 | 2023-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $81.72 | 2022-2024 | |
| Esperion Therapeutics, INC. | $56.68 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.47 | 2024-2025 | Verquvo |
| Novo Nordisk INC | $52.62 | 2021 | |
| Cook Medical LLC | $49.47 | 2019-2023 | Zilver Ptx |
| Abiomed | $34.33 | 2024 | Impella |
| Philips North America LLC | $29.76 | 2024 | (Br3) Coronary Other |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.31 | 2023 | Jardiance |
| Astellas Pharma US INC | $24.94 | 2020 | |
| Ancora Heart, INC. | $22.27 | 2024 | Accucinch |
| Novartis Pharmaceuticals Corporation | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Argulian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.